Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2017 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.

Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Glenmark: Strong growth continues - Views on News from Equitymaster
  • E-MAIL
  • A  A  A
  • Feb 11, 2002

    Glenmark: Strong growth continues

    Glenmark Pharma continues to outperform industry growth rates. The company has recorded a 31% growth in topline. Profit before tax registered a growth of 54%, on the back of sharp rise in operating margins. Depreciation and Interest showed a sharp spurt however, on account of commissioning of its new Goa facility. The company has also performed impressively on the export front.

    (Rs m) 3QFY01 3QFY02 % Change 9m FY01 9m FY02 % Change
    Sales 509 667 30.9% 1,430 1,710 19.6%
    Other Income 5 1 -87.5% 9 2 -79.6%
    Expenditure 417 525 25.9% 1,206 1,353 12.2%
    Operating Profit (EBDIT) 92 142 53.5% 224 357 59.1%
    Operating Profit Margin (%) 18.1% 21.3% 15.7% 20.9%
    Interest 29 33 14.0% 56 95 69.0%
    Depreciation 11 22 90.1% 28 64 128.1%
    Profit before Tax 57 88 54.4% 149 200 34.2%
    Tax 5 33 574.0% 13 40 217.5%
    Profit after Tax/(Loss) 52 55 5.3% 136 160 17.4%
    Net profit margin (%) 10.2% 8.2%   9.5% 9.4%  
    No. of Shares (eoy) (m) 10.1 10.1   10.1 10.1  
    Diluted Earnings per share* 20.7 21.8   18.0 21.1  
    P/E (at current price)   11.8   12.1  
    (*- annualised)            

    To strengthen its position in the dermatology and respiratory segments, the company had acquired three large brands of Lyka Laboratories last year for a consideration of Rs 345 m. These include Alex (cough preparation), Flucort (dermatology steroid) and Sensur (pain balm). All the three brands have performed well during the year. The company is consicously reducing its dependence on the dermatology segment by launching products across various therapeutic segment. Some of the company's products launched in the anti-diabetes and cardiovascular segment seem to be doing well.

    R&D efforts of the company also seem to be progressing well. The research activities of the company are focused in the areas of diabetes, asthma and pain management.Two molecules of the company are in advanced pre-clinical trial stage.

  • Read our recent company update

    It seems that the company is taking all the right steps to maintain its growth trajectory in future. However, while growth in the domestic market is hard to come, the company is a bit late in cashing on the generic opportunity as it lacks an ANDA (Abbreviated New Drug Application) pipeline. In the domestic market on the other hand, the company faces stiff competition and it would be hard to maintain premium pricing going forward. Considering other peer valuations and a P/E multiple of 12x 9 months annualised earnings, the stock looks fairly valued at the current market price of Rs 255.



    Equitymaster requests your view! Post a comment on "Glenmark: Strong growth continues". Click here!


    More Views on News

    Glenmark Pharma: Lower Zetia Sales leads to Subdued Growth (Quarterly Results Update - Detailed)

    May 18, 2017

    Base price erosion in the US and lower Zetia sales impacts profits.

    Glenmark: Zetia Generics Boost Growth (Quarterly Results Update - Detailed)

    Feb 15, 2017

    Glenmark has announced its 3QFY16 results. The company has reported 41% YoY growth in net sales and 143.2% YoY increase in net profits. Here is our analysis of the results.

    Glenmark: High Costs hit the Bottom line (Quarterly Results Update - Detailed)

    Nov 8, 2016

    Glenmark has announced its 2QFY16 results. The company has reported 15.7% YoY growth in net sales and 3.5% YoY increase in net profits. Here is our analysis of the results.

    Sun Pharma: Bottomline Slips into the Red Amidst Challenging Environment (Quarterly Results Update - Detailed)

    Aug 14, 2017

    A challenging environment and one-time expense pushes Sun Pharma into a loss in the first quarter.

    Lupin: Bigger Challenges or Bigger Margin of Safety? (Quarterly Results Update - Detailed)

    Aug 14, 2017

    GST impact coupled with price erosion in US leads to lower profits for the quarter.

    More Views on News

    Most Popular

    Demonetisation Barely Made Any Difference to Tax Collections(Vivek Kaul's Diary)

    Aug 7, 2017

    The data tells us quite a different story from the one the government is trying to project.

    A 'Backdoor' to Multibaggers: It's Like Investing in Asian Paints Ten Years Ago(The 5 Minute Wrapup)

    Aug 10, 2017

    Don't miss these proxy bets on growing companies or in a few years you will be looking back with regret.

    Should You Invest In Bharat-22 ETF? Know Here...(Outside View)

    Aug 8, 2017

    Bharat-22 is one of the most diverse ETFs offered so far by the Government. Know here if you should invest...

    Signs of Life in the India VIX(Daily Profit Hunter)

    Aug 12, 2017

    The India VIX is up 36% in the last week. Fear has gone up but is still low by historical standards.

    7 Financial Gifts For Your Sister This Raksha Bandhan(Outside View)

    Aug 7, 2017

    Raksha Bandhan signifies the brother-sister bond. Here are 7 thoughtful financial gifts for sisters...

    Copyright © Equitymaster Agora Research Private Limited. All rights reserved.
    Any act of copying, reproducing or distributing this newsletter whether wholly or in part, for any purpose without the permission of Equitymaster is strictly prohibited and shall be deemed to be copyright infringement.

    LEGAL DISCLAIMER: Equitymaster Agora Research Private Limited (hereinafter referred as 'Equitymaster') is an independent equity research Company. Equitymaster is not an Investment Adviser. Information herein should be regarded as a resource only and should be used at one's own risk. This is not an offer to sell or solicitation to buy any securities and Equitymaster will not be liable for any losses incurred or investment(s) made or decisions taken/or not taken based on the information provided herein. Information contained herein does not constitute investment advice or a personal recommendation or take into account the particular investment objectives, financial situations, or needs of individual subscribers. Before acting on any recommendation, subscribers should consider whether it is suitable for their particular circumstances and, if necessary, seek an independent professional advice. This is not directed for access or use by anyone in a country, especially, USA or Canada, where such use or access is unlawful or which may subject Equitymaster or its affiliates to any registration or licensing requirement. All content and information is provided on an 'As Is' basis by Equitymaster. Information herein is believed to be reliable but Equitymaster does not warrant its completeness or accuracy and expressly disclaims all warranties and conditions of any kind, whether express or implied. Equitymaster may hold shares in the company/ies discussed herein. As a condition to accessing Equitymaster content and website, you agree to our Terms and Conditions of Use, available here. The performance data quoted represents past performance and does not guarantee future results.

    SEBI (Research Analysts) Regulations 2014, Registration No. INH000000537.

    Equitymaster Agora Research Private Limited. 103, Regent Chambers, Above Status Restaurant, Nariman Point, Mumbai - 400 021. India.
    Telephone: +91-22-61434055. Fax: +91-22-22028550. Email: info@equitymaster.com. Website: www.equitymaster.com. CIN:U74999MH2007PTC175407

    Become A Smarter Investor In
    Just 5 Minutes

    Multibagger Stocks Guide 2017
    Get our special report, Multibagger Stocks Guide (2017 Edition) Now!
    We will never sell or rent your email id.
    Please read our Terms


    Aug 18, 2017 (Close)


    • Track your investment in GLENMARK PHARMA with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
    • Add To MyStocks



    Detailed Quarterly Results With Charts